Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Launched by FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL · Mar 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for women with early-stage breast cancer that tests positive for HER2, particularly those who still have some cancer left after initial treatment. The trial aims to find out whether continuing the original targeted therapy is more effective than using a combination of trastuzumab (a common breast cancer drug) with pyrotinib and capecitabine (two other medications) after surgery. This is important for patients who didn’t achieve a complete response to their earlier treatments.

To be eligible for the trial, women must be between the ages of 18 and 75 and have been diagnosed with invasive breast cancer that is HER2 positive. They should have received at least 9 weeks of treatment with trastuzumab and chemotherapy before their surgery. Participants will be randomly assigned to one of the two treatment groups and will be monitored for how well the treatments work and any side effects they might experience. This trial is currently recruiting participants, so it’s a chance for eligible women to potentially benefit from new treatment options while contributing to important research.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female patients aged ≥ 18 years and ≤ 75 years old with primary breast cancer
• • ECOG score 0 \~ 1
• • Breast cancer meets the following criteria: 1）Histologically or pathologically confirmed invasive breast cancer, primary tumor stage determined by standard evaluation methods：cT1-4/N0-3/M0. 2）Pathologically confirmed HER2-expressing positive breast cancer, defined as \> 10% immunoreactive cells with immunohistochemical (IHC) score of 3 + or in situ hybridization (ISH) results of HER2 gene amplification. 3)Known hormone receptor status (ER and PgR). 4)Neoadjuvant therapy (including: at least 9 weeks of trastuzumab treatment and at least 9 weeks of taxane chemotherapy)
• • Primary breast cancer lesion or lymph node invasive cancer confirmed by pathology after neoadjuvant therapy (residual invasive breast cancer lesion \> 2 cm or axillary lymph node positive with macrometastasis assessed by central laboratory)
• • No more than 12 weeks between end of surgery (without post-operative radiotherapy) and randomisation or 6 weeks between end of post-operative radiotherapy and randomisation
• * Required laboratory values including following parameters:
• • ANC: ≥ 1.5 x 109/L Platelet count: ≥ 90 x 109/L Hemoglobin: ≥ 9.0 g/dL Total bilirubin: ≤ 1.5 x upper limit of normal, ULN ALT and AST: ≤ 1.5 x ULN BUN and creatine clearance rate: ≥ 50 mL/min LVEF: ≥ 55% QTcF: \< 470 ms
• Exclusion Criteria:
• • 1) Stage IV (metastatic) breast cancer;
• • 2) inflammatory breast cancer;
• • 3) Previous anti-tumor therapy or radiotherapy for any malignancy, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma;
• • 4) Receiving anti-tumor therapy in other clinical trials, including bisphosphonate therapy or immunotherapy (except radiotherapy and endocrine therapy during treatment);
• • 5) Receiving any anti-tumor therapy within 28 days before enrollment;
• • 6) Peripheral neuropathy ≥ Grade 2 as specified by NCI CTCAE;
• • 7) Receiving pyrrolidone or other anti-HER2 tyrosine kinase inhibitors;
• • 8) Receiving anthracycline therapy with cumulative doses as follows: adriamycin \> 240 mg/m2, epirubicin \> 480 mg/m2;
• • 9) Receiving major surgery unrelated to breast cancer before randomization, or the patient has not fully recovered from surgery